Radiotherapy Clinical Trials in Beijing, Beijing Municipality
17 recruitingBeijing, Beijing Municipality, China
Showing 1–17 of 17 trials
Recruiting
Phase 2
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
Lung CancerRadiotherapyImmune Checkpoint Inhibitor+1 more
Tianjin Medical University Cancer Institute and Hospital30 enrolled3 locationsNCT07058948
Recruiting
Not Applicable
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
Diffuse Large B Cell LymphomaRadiotherapyCAR-T+1 more
Peking Union Medical College Hospital20 enrolled1 locationNCT05514327
Recruiting
Phase 3
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Whole-Brain Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences134 enrolled1 locationNCT07443397
Recruiting
Not Applicable
Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)
Radiotherapy Side EffectSoft Tissue SarcomaRetroperitoneal Sarcoma+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT05224934
Recruiting
Not Applicable
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
Radiotherapy Side EffectProstate CancerOligometastatic Disease+4 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT05183074
Recruiting
Not Applicable
Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer
Endometrial CancerSide EffectsRadiotherapy, Adjuvant+2 more
Xiaorong Hou20 enrolled1 locationNCT07116213
Recruiting
Phase 2
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
SafetyLocally Advanced Non-Small Cell Lung CancerThoracic Radiotherapy
JIANYANG WANG44 enrolled1 locationNCT07037680
Recruiting
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
RadiotherapyLung Cancer (NSCLC)Neoadjuvant Immunotherapy+1 more
Peking University Cancer Hospital & Institute500 enrolled4 locationsNCT06926179
Recruiting
Phase 2
Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences40 enrolled1 locationNCT06667622
Recruiting
Phase 2Phase 3
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Cervical CancerConcurrent ChemoradiotherapyNeoadjuvant Chemoimmunotherapy+1 more
Tongji Hospital440 enrolled12 locationsNCT06288373
Recruiting
Not Applicable
Super-Hypofractionated Partial Breast Irradiation
Breast CancerRadiotherapy Side Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT06615466
Recruiting
Not Applicable
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
CDK4/6 InhibitorChemotherapeutic ToxicityTrastuzumab+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences148 enrolled1 locationNCT06197581
Recruiting
Spectral CT in Radiotherapy for Cervical Cancer
Cervical CancerRadiotherapy
Peking Union Medical College Hospital150 enrolled1 locationNCT06433817
Recruiting
Phase 2
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
Hepatocellular CarcinomaRadiotherapyPembrolizumab+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences30 enrolled1 locationNCT06389422
Recruiting
Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Thoracic CancerRadiotherapySafety and Efficacy
Peking University Third Hospital120 enrolled1 locationNCT05349552
Recruiting
Phase 2Phase 3
Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer
Breast CancerOptical Surface Monitoring TechnologyLarge-segment Radiotherapy
Peking Union Medical College Hospital556 enrolled1 locationNCT05804916
Recruiting
Phase 2
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
Cervical CarcinomaImmunotherapyImmune Checkpoint Inhibitor+6 more
Lei Li92 enrolled1 locationNCT05311566